James L. Kirkland and dasatinib
A mouse kidney finding accompanies the link between Kirkland and dasatinib, but the underlying study, his involvement, and dasatinib's individual contribution remain unknown.
James L. Kirkland and dasatinib
A saved excerpt reports that dasatinib combined with quercetin reduced kidney inflammation, senescent cell abundance, and kidney injury in diabetic mice. Dasatinib is an anticancer drug also studied as a senolytic, a compound intended to remove senescent cells.
James L. Kirkland, a physician-scientist, helped establish cellular senescence as a therapeutic target for age-related disease. His profile connects him with dasatinib, quercetin, and senolytics. However, the underlying study's authors and Kirkland's involvement in the experiment are unknown. The excerpt describes a result obtained with a drug combination, so it cannot establish dasatinib's individual contribution. It also does not establish that reducing senescent cell abundance caused the improvements in kidney outcomes. No human kidney treatment outcomes are provided.
Assessing the result requires finding the primary paper and checking its authors, diabetes model, doses, sample size, control groups, effect sizes, and statistical analysis.
This edge has a concrete experimental result and a clear verification path, but the available excerpt leaves authorship, study conditions, and the separate contribution of dasatinib unresolved.